Skip to main content
Journal of Diabetes and Metabolic Disorders logoLink to Journal of Diabetes and Metabolic Disorders
. 2023 Jul 28;22(2):1011–1019. doi: 10.1007/s40200-023-01267-5

Global prevalence of sexual dysfunction among women with metabolic syndrome: a systematic review and meta-analysis

Nader Salari 1, Mona Moradi 2, Amin Hosseinian-Far 3, Yassaman Khodayari 2, Masoud Mohammadi 4,✉
PMCID: PMC10638256  PMID: 37975075

Abstract

Background

Sexual dysfunction is a common disorder among women, especially during menopause. Metabolic syndrome is a multifactorial disease that, according to previous studies, there is a relationship between the metabolic syndrome and sexual dysfunction among women. The aim of this systematic review and meta-analysis is to obtain the prevalence of Female Sexual Dysfunction (FSD) among women with metabolic syndrome, and to analyze available related evidence.

Methods

In this systematic review and meta-analysis, the keywords of MeSH, female sexual dysfunction, FSD, metabolic syndrome were searched in PubMed, Web of Science, Scopus, Science Direct and Google Scholar. The searches were conducted without a lower time limit and until May 2022.

Results

The prevalence of FSD among women with metabolic syndrome was found to be 39.3% (95% CI: 28.3–51.5). In the subgroup analysis and in the review of 4 studies, the prevalence of sexual dysfunction in postmenopausal women with metabolic syndrome was 49.8% (95% CI: 26.1–73.6). Analyzing the results of the meta-regression test in examining the effect of the three factors of sample size, year of the study, age, and BMI of the patients on the heterogeneity of the meta-analysis, showed that with the increase of the sample size, the prevalence of sexual dysfunction among women with metabolic syndrome decreases (p < 0.05). Moreover, the prevalence of sexual dysfunction among women with metabolic syndrome increases (p < 0.05) with the increase in the years of conducting studies and the mean of age of women with metabolic syndrome. Also, with increasing mean of BMI of female patients with metabolic syndrome, the prevalence of sexual dysfunction in these women also increases (p < 0.05).

Conclusion

Female sexual dysfunction is a global health problem that can affect women’s life to a great extent. Metabolic syndrome, which is a set of factors such as obesity, high blood pressure, and diabetes, affects sexual dysfunction in women. From this study, it can be concluded that there is a close relationship between metabolic syndrome and female sexual dysfunction.

Keywords: FSD, BMI, Metabolic syndrome, Female sexual dysfunction, Meta-analysis

Background

According to the definition of the World Health Organization, sexual health is a state of physical, emotional, psychological, and social well-being related to sexuality [1–3]. Female Sexual Dysfunction (FSD) is one of the important public health challenges. FSD consists of several disorders classified into diagnostic categories, sexual desire, arousal, orgasm, and pain [4–7]. Menopause is also one of the factors affecting women’s sexual performance, and FSD is more common among postmenopausal women with Metabolic syndrome (MetS) [7]. Up until 2007, FSD was considered to be psychological in nature, yet, it is now recognized as a complex neurovascular phenomenon under influence of psychological, neurological, and hormonal factors [8–10].

Age-related changes lead to changes in sexual performance, which may also lead to sexual dysfunction [8, 9]. Other factors affecting FSD include the relationship between a woman and her husband, and also behavior, and metabolic changes [8].

According to a study conducted in the United States, the prevalence of FSD among women aged 18 to 59 years was 43% in late 90’s [5]. Studies conducted in Korea showed that 37% of women aged 40 to 80 were affected by some form of FSD [11].

Metabolic syndrome (MetS), also known as syndrome X, insulin resistance, or dysmetabolic syndrome, is a multifactorial disease characterized by the co-occurrence of several disorders including glucose intolerance/diabetes, central obesity, elevated serum triglyceride levels, low high-density lipoprotein (HDL) and high blood pressure [3, 12]. The prevalence of MetS increases sharply after middle age, with a prevalence rate of 23.4% reported among American women [13], and 17.8% among Korean women [14].

One of the possible risk factors for FSD may be vascular dysfunction due to MetS, which leads to impaired tissue oxygenation and subsequent structural and functional damage to a female reproductive system [15].

There is evidence that shows that women with metabolic syndrome have more sexual disorders (decrease in sexual activity, desire, and satisfaction) than women without MetS [6, 16].

Considering that the reports of different studies on the prevalence of sexual dysfunction in women with metabolic syndrome report heterogeneous and different values, the purpose of the present study is to determine the overall prevalence of sexual intercourse with a systematic review and meta-analysis in order to provide homogeneous information to health policy makers.

Methods

PubMed, Web of Science, Scopus, Science Direct, and Google Scholar repositories were searched using the keywords of female sexual dysfunction, metabolic syndrome, FSD, and MetS. In order to maintain the comprehensiveness of the search, no restrictions were applied to the year of publication of the articles, and information on the identified articles was transferred into the EndNote reference management software. To maximize the number of relevant studies, the list of references used in the identified related articles was reviewed manually. The relevant studies were searched without a time interval until April 2022, and then the searches were updated once again in May 2022 so that no articles were missed.

Study inclusion and exclusion criteria

Study inclusion criteria were: cross-sectional studies, observational studies (cohort, case-control, etc.), studies with full-text available.

Study exclusion criteria were: case series, case reports, review studies, duplicates, studies published in a language other than English.

Study selection

The study selection process was conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. EndNote reference management software was used to organize the studies. At first, duplicate articles in different databases were excluded from this study. In the initial evaluation, the titles and abstracts of the articles were carefully examined and articles unrelated to the purpose of the research were removed. In the second stage, i.e., eligibility evaluation, the full text of the relevant articles was examined and the studies that met the inclusion criteria were included. To increase validity and avoid any potential bias, an initial screening was conducted by two researchers (MM and HZ) to determine whether the eligibility criteria were met. In cases where there was a disagreement between the two reviewers, a third reviewers supported the review team to reach a consensus. Finally, 10 studies entered the third stage, for quality evaluation.

Quality evaluation

To evaluate the quality of articles, a checklist was used according to observational studies. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist consists of six scales including: title, abstract, introduction, methods, results and discussion. In total, these 6 scales are comprised of 32 subscales (items). The 32 items include different methodological aspects of the study, i.e., title, statement of the problem, study objectives, type of study, statistical population of the study, sampling strategy, determining the appropriate sample size, definition of variables and procedures, data collection methods, statistical analysis techniques, and findings. Any article that fulfils any of the subscales receives a point in STROBE scoring. Accordingly, articles with a score of 16 and above were considered to be of medium and high methodological quality respectively, and articles with a score below 16 were considered to be of low methodological quality and were therefore excluded.

Data extraction

Data extraction was conducted by two researchers using a different pre-prepared checklist. This checklist included: author’s name, year of publication, research location, sample size, age of participants, data collection method, and prevalence percentage.

Results

In this systematic review and meta-analysis, studies were systematically evaluated according to the PRISMA guidelines. Throughout the search process, 803 possible relevant articles were identified initially and transferred to the EndNote reference management software. In the initial stage of screening, duplicate studies and studies that met the exclusion criteria (case series, case reports, review studies, and studies published in a language other than English) were excluded from the study. According to this, 346 articles were removed due to duplication. In the screening phase, the title and abstract of the studies were reviewed and 509 articles were excluded based on the inclusion and exclusion criteria. In the eligibility evaluation phase, 112 articles were excluded through examination of full text and in accordance with the inclusion and exclusion criteria. In the quality evaluation phase, through the study of the full text of the articles and based on the scores obtained from the STROBE checklist. Finally, 9 studies were included for the final evaluation. The final included articles were prepared for the meta-analysis were reviewed (Fig. 1). Moreover, characteristics of the 9 selected studies were extracted and are presented in Table 1.

Fig. 1.

Fig. 1

PRISMA flow diagram for study selection

Table 1.

Summary of characteristics of the included studies

Author Year Region Study population Prevalence Age (Mean ± SD) BMI (Mean ± SD) Status of women Instrument
K. Esposito et al. [2] 2005 Italy 120 9.2% 40.6 ± 5.7 28.1 ± 3.4 – (FSFI)
G.M.D. da Silva et al. [3] 2020 Brazil 153 61.4% 54.4 postmenopausal women (FSFI)
S. Alivisi et al. [4] 2014 Italy 98 19.4% 41.3 ± 8.7 30.8 ± 4.1 postmenopausal women (FSFI), (FSDS), (MHQ)
Y-H. Kim et al. [5] 2011 Korea 94 52.1% 50 (47–55) 24.6 – (FSFI)
A. Otunctemur et al. [7] 2015 Turkey 200 41% 48.5 ± 8.1 28.8 ± 2.7 – (FSFI)
C.A. Politano et al. [8] 2015 Brazil 256 32% 40–60 – – (SPEQ)
V. Martelli et al. [9] 2012 Italy 103 37.9% 57.7 ± 4.9 29.4 ± 4.6 postmenopausal women (FSFI), (FSDS), (MHQ)
M. Baldassarre et al. [17] 2016 Italy 182 34.6% 53 (46–60) 29.2 – (FSFI), (FSDS), (MHQ), (FRS)
S.W. Lee et al. [18] 2012 Korea 64 81.3 56.1 ± 6.8 24.5 ± 2.5 postmenopausal women (MRS), (NCEP-ATP III)

Female Sexual Function Index (FSFI)

Female Sexual Distress Scale (FSDS)

Middlesex Hospital Questionnaire (MHQ)

Framingham risk score (FRS)

Menopause Rating Scale (MRS)

Short Personal Experience Questionnaire (SPEQ)

Adult Treatment Panel III (NCEP-ATP III)

Examining the results of the heterogeneity of the studies with the I2 test (93.7%) indicated high heterogeneity among the studies, and therefore, random effects model was adopted to analyze the results. It was found that the publication bias was not significant (p: 0.928) (Fig. 2).

Fig. 2.

Fig. 2

Funnel plot of publication bias among the reviewed studies

In a review of 9 studies with an age range of 20 to 60 years and a sample size of 1336 people, the overall pooled prevalence of sexual dysfunction among women with metabolic syndrome was found as 39.3% (95% CI: 28.3–51.5) in accordance with the results from our meta-analysis (Fig. 3). In 4 studies that investigated sexual dysfunction in postmenopausal women with metabolic syndrome [3, 4, 9, 18], with a total sample size of 418 women, a subgroup analysis was performed, based on which the publication bias was not significant (p: 0.980) and the overall prevalence was obtained 49.8% (95% CI: 26.1–73.6).

Fig. 3.

Fig. 3

Forest plot outlining the overall pooled prevalence of sexual dysfunction among women with metabolic syndrome based on the random effects model; The diamond shape denotes the pooled prevalence, and each black square represents reported prevalence within its respective study

In order to investigate the heterogeneity in the studies and the factors affecting it, three factors of sample size, year of study, age, and BMI of patients were selected. A meta-regression analysis concluded that, with the increase of sample size, the prevalence of sexual dysfunction among women with metabolic syndrome decreases (p < 0.05) (Fig. 4). Also, with the increase in the number of years of conducting studies, the prevalence of sexual dysfunction in women with metabolic syndrome increases (p < 0.05) (Fig. 5). The meta-regression results also showed that with increasing mean of age of female patients with metabolic syndrome, the prevalence of sexual dysfunction in these women also increases (p < 0.05) (Fig. 6). The meta-regression results also showed that with increasing mean of BMI of female patients with metabolic syndrome, the prevalence of sexual dysfunction in these women also increases (p < 0.05) (Fig. 7).

Fig. 4.

Fig. 4

Meta-regression of prevalence of sexual dysfunction in women with metabolic syndrome based on sample size

Fig. 5.

Fig. 5

Meta-regression of the prevalence of sexual dysfunction in women with metabolic syndrome based on year of study

Fig. 6.

Fig. 6

Meta-regression of the prevalence of sexual dysfunction in women with metabolic syndrome based on age (Mean) of female patients

Fig. 7.

Fig. 7

Meta-regression of the prevalence of sexual dysfunction in women with metabolic syndrome based on BMI (Mean) of female patients

Discussion

The present study is the first systematic review and meta-analysis on the global prevalence of sexual dysfunction among women with metabolic syndrome. This study was conducted using the most optimal statistical methods of secondary analysis, and meta-analysis was attempted on the reported results of 9 qualified studies. The total studied population is 1336 and the prevalence of sexual dysfunction in women with metabolic syndrome is found as 39.3%.

The results of the reviewed articles show that there is a direct relationship between metabolic syndrome and female sexual dysfunction. It was reported based on the results of a study conducted on female patients with metabolic syndrome and a matched control group that the FSFI of women with metabolic syndrome (23.2 ± 5.4 vs 30.1 ± 4.7) was lower compared to women without metabolic syndrome [2]. In a study conducted by da Silva et al., based on the analysis of FSFI domain scores (i.e., desire, arousal, relaxation, orgasm, and satisfaction), it was found that FSFI domain scores were lower among postmenopausal women with MetS (26.8 vs 23.1), which led to a higher incidence of FSD among postmenopausal women with MetS [3]. In a study conducted in the Italian population of women, the prevalence of FSD in women with metabolic syndrome was reported as 33%, and on the other hand, in the control group, the prevalence was 19%. The same study also reported that there is a higher prevalence of FSD among women with MetS [9]. Nonetheless, the association between MetS and FSD is controversial. Several other studies have failed to find a close relationship between MetS and FSD [5, 8, 19, 20]. Politano et al. consider sexual dysfunction in women’s partners as the only sexual factor associated with MetS [8]. Also, the study of Poh Yih Chew also reports in the results of their meta-analysis that men who partner with women with sexual dysfunction or have wives with this disorder, these men face an increased risk of erectile and ejaculation disorders [21].

Female sexual function is a combination of endocrine, vascular, and neuromuscular factors that regulate the important stages of women’s sexual response, such as increasing blood flow in the genital area, increasing the diameter and length of the clitoris, increasing the diameter of the vaginal canal, and lubrication [22, 23]. Pelvic vascular damage and neuropathy caused by some metabolic factors such as dyslipidemia, glucose intolerance, insulin resistance, diabetes mellitus, and increased systemic arterial blood pressure can cause clitoral insufficiency and a decrease in vaginal blood supply, which ultimately leads to FSD [23–28]. Some studies have also considered obesity as one of the influential factors of women’s sexual disorder, in a way that among overweight women, there is less sexual desire, lubrication, and orgasm [29–31]. In a study conducted in US, focusing on sexual disorders among obese population, reported that the prevalence of female sexual disorders is between 7 to 22% [32].

The results of the meta-regression test in this study reported that as the age of female patients with metabolic syndrome increases, the prevalence of sexual dysfunction in these women increases. The evidence reported in Hayes et al.’s study shows that women’s sexual performance declines with age, as it is reported that this decline begins in women’s late 20s to late 30s and desire, the frequency of orgasm, and sexual intercourse decreases with age [33].

Lifestyle changes, especially focusing on regular activities and a healthy diet, can be effective in preventing and treating sexual problems [29]. Mediterranean diet that includes fruits, whole vegetables, grains, nuts, and fish, has been reported as a possible intervention to improve sexual health in women [34, 35]. Esposito in a study investigated the effect of the Mediterranean diet on women’s sexual problems; In women who followed the Mediterranean dietary pattern, an improvement in FSFI score was observed [34].

Risky behaviors such as smoking, and alcohol have a negative effect on sexual performance. In fact, alcohol is a depressant of the central nervous system that slows down brain function, breathing, and blood flow, and reduces vaginal lubrication in women [36]. Few studies have been conducted on the relationship between smoking and female’s sexual performance; the results of these studies did not report a relationship between smoking and sexual dysfunction among women [37, 38].

Physical activity reduces the risk of chronic diseases (such as diabetes or high blood pressure), and sexual disorders [39]. Among women, exercise can improve many common symptoms of menopause, especially mood, sleep, anxiety, depression, and musculoskeletal disorders [40–42]. In a study, postmenopausal women with a consistent physical activity have a better body image. Such physical activity also helps them to improve their self-esteem, express their emotions, and maintain an adequate and appropriate BMI [43]. In a study by Cabral et al., the presence of sexual dysfunction in women was measured using FSFI, and the results showed that sexual dysfunction was present in 67% of women who had a sedentary lifestyle, yet only 57.6% of those who had regular activity were suffering from FSD. Based on these data, it can be concluded that lack of physical activity in postmenopausal women increases the risk of FSD by 2.1 times [44]. Based on the findings of a study, which investigated the effect of yoga on sexual dysfunction, it was shown that yoga is a safe and effective treatment for sexual dysfunction and is a preventive method to reduce the risk of metabolic factors in women with MetS [45].

The most important strength of this study is the use of meta-regression analysis in order to investigate heterogeneity factors, which explains well the effect of these factors on the overall result. Our study has limitations, all the studies we analyzed were cross-sectional, cohort, or case-control studies that examined the condition of individuals in a certain period of time. This decision was made in order to collect all studies and avoid ignoring all studies in this field, but the methods of these studies can be different.

Conclusion

Our findings show that the overall prevalence of female sexual dysfunction in women with metabolic syndrome is high. Few studies have been conducted in this field, and therefore there is a need for further research to obtain richer results. Sexual dysfunction in women affects their personal and social life, and considering this, it is recommended that more studies are conducted to evaluate the relationship between metabolic syndrome and sexual dysfunction among women, as well as to better understand factors affecting women’s sexual health.

Acknowledgements

We would like to thank the esteemed officials of the Student Research Committee of Kermanshah University of Medical Sciences for the financial affords of this study.

Authors’contributions

NS and YK and MM1 and MM2 contributed to the design, MM2 statistical analysis, participated in most of the study steps. MM1 and Yk and AH prepared the manuscript. MM1 and MM2 and YK and HZ and MM and YK assisted in designing the study, and helped in the, interpretation of the study. All authors have read and approved the content of the manuscript.

Data availability

Datasets are available through the corresponding author upon reasonable request.

Declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no conflict of interest.

Footnotes

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  • 1.Sancak EB, Oguz S, Akbulut T, Uludag A, Akbas A, Kurt O, Akbulut MF. Female sexual dysfunction in androgenetic alopecia: case-control study. Can Urol Assoc J. 2016; 10.5489/cuaj.3582. [DOI] [PMC free article] [PubMed]
  • 2.Esposito K, Ciotola M, Marfella R, Di Tommaso D, Cobellis L, Giugliano D. The metabolic syndrome: a cause of sexual dysfunction in women. Int J Impot Res. 2005;17(3):224–226. doi: 10.1038/sj.ijir.3901310. [DOI] [PubMed] [Google Scholar]
  • 3.da Silva GMD, Lima SMRR, Reis BF, Macruz CF, Postigo S. Prevalence of hypoactive sexual desire disorder among sexually active postmenopausal women with metabolic syndrome at a public Hospital Clinic in Brazil: a cross-sectional study. Sex Med. 2020;8(3):545–553. doi: 10.1016/j.esxm.2020.05.008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Alvisi S, Baldassarre M, Lambertini M, Martelli V, Berra M, Moscatiello S. Maria Cristina Meriggiola, Stefano Venturoli, Giulio Marchesini, sexuality and psychopathological aspects in premenopausal women with metabolic syndrome. Sex Med. 2020;8(3):545–553. doi: 10.1111/jsm.12585. [DOI] [PubMed] [Google Scholar]
  • 5.Kim YH, Kim SM, Kim JJ, Cho IS, Jeon MJ. Does metabolic syndrome impair sexual function in middle- to old-aged women? J Sex Med. 2011;8(4):1123–1130. doi: 10.1111/j.1743-6109.2010.02174.x. [DOI] [PubMed] [Google Scholar]
  • 6.Maiorino MI, Bellastella G, Giugliano D, Esposito K. From inflammation to sexual dysfunctions: a journey through diabetes, obesity, and metabolic syndrome. J Endocrinol Investig. 2018;41(11):1249–1258. doi: 10.1007/s40618-018-0872-6. [DOI] [PubMed] [Google Scholar]
  • 7.Otunctemur A, Dursun M, Ozbek E, Sahin S, Besiroglu H, Koklu I, et al. Effect of metabolic syndrome on sexual function in pre- and postmenopausal women. J Sex Marital Ther. 2015;41(4):440–449. doi: 10.1080/0092623X.2014.918068. [DOI] [PubMed] [Google Scholar]
  • 8.Politano CA, Valadares AL, Pinto-Neto A, et al. The metabolic syndrome and sexual function in climacteric women: a crosssectional study. J Sex Med. 2015;12:455–462. doi: 10.1111/jsm.12749. [DOI] [PubMed] [Google Scholar]
  • 9.Martelli V, Valisella S, Moscatiello S, Matteucci C, Lantadilla C, Costantino A, et al. Prevalence of sexual dysfunction among postmenopausal women with and without metabolic syndrome. J Sex Med. 2012;9(2):434–441. doi: 10.1111/j.1743-6109.2011.02517.x. [DOI] [PubMed] [Google Scholar]
  • 10.Raina R, Pahlajani G, Khan S, Gupta S, Agarwal A, Zippe CD. Female sexual dysfunction: classification, pathophysiology, and management. Fertil Steril. 2007;88(5):1273–1284. doi: 10.1016/j.fertnstert.2007.09.012. [DOI] [PubMed] [Google Scholar]
  • 11.Moreira ED, Jr, Kim SC, Glasser D, Gingell C. Sexual activity, prevalence of sexual problems, and associated help-seeking patterns in men and women aged 40-80 years in Korea: data from the global study of sexual attitudes and behaviors (GSSAB) J Sex Med. 2006;3(2):201–211. doi: 10.1111/j.1743-6109.2006.00210.x. [DOI] [PubMed] [Google Scholar]
  • 12.Choy CL, Sidi H, Koon CS, et al. Systematic review and Meta-analysis for sexual dysfunction in women with hypertension. J Sex Med. 2019;16:1029–1048. doi: 10.1016/j.jsxm.2019.04.007. [DOI] [PubMed] [Google Scholar]
  • 13.Ford ES, Giles WH, Mokdad AH. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care. 2004;27(10):2444–2449. doi: 10.2337/diacare.27.10.2444. [DOI] [PubMed] [Google Scholar]
  • 14.Park HS, Kim SM, Lee JS, Lee J, Han JH, Yoon DK, Baik SH, Choi DS, Choi KM. Prevalence and trends of metabolic syndrome in Korea: Korean National Health and nutrition survey 1998-2001. Diabetes Obes Metab. 2007;9(1):50–58. doi: 10.1111/j.1463-1326.2005.00569.x. [DOI] [PubMed] [Google Scholar]
  • 15.Ponholzer A, Temml C, Rauchenwald M, Marszalek M, Madersbacher S. Is the metabolic syndrome a risk factor for female sexual dysfunction in sexually active women? Int J Impot Res. 2008;20(1):100–104. doi: 10.1038/sj.ijir.3901605. [DOI] [PubMed] [Google Scholar]
  • 16.Trompeter SE, Bettencourt R, Barrett-Connor E. Metabolic syndrome and sexual function in postmenopausal women. Am J Med. 2016;129(12):1270–1277.e1. doi: 10.1016/j.amjmed.2016.03.039. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Baldassarre M, Alvisi S, Mancini I, Moscatiello S, Marchesini G, Seracchioli R. Cristina Meriggiola M, impaired lipid profile is a risk factor for the development of sexual dysfunction in women. J Sex Med. 2016;13(1):46–54. doi: 10.1016/j.jsxm.2015.11.005. [DOI] [PubMed] [Google Scholar]
  • 18.Lee SW, Kwon DJ, Kim JH, Jo HH, Kim MR, You YO. Association between menopausal symptoms and metabolic syndrome in postmenopausal women. Arch Gynecol Obstet. 2012;285(2):541–548. doi: 10.1007/s00404-011-2016-5. [DOI] [PubMed] [Google Scholar]
  • 19.Blümel JE, Chedraui P, Baron G, Belzares E, Bencosme A, Calle A, et al. Sexual dysfunction in middle-aged women: a multicenter Latin American study using the female sexual function index. Menopause. 2009;16(6):1139–1148. doi: 10.1097/gme.0b013e3181a4e317. [DOI] [PubMed] [Google Scholar]
  • 20.Dombek K, Capistrano EJ, Costa AC, Marinheiro LP. Metabolic syndrome and sexual function in postmenopausal women. Arch Endocrinol Metab. 2016;60:545–553. doi: 10.1590/2359-3997000000194. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Chew PY, Choy CL, Sidi H b, Sahimi HMS, Samad FDA, Ravindran A. The association between female sexual dysfunction and sexual dysfunction in the male partner: a systematic review and Meta-analysis. JSexMed. 2021;18:99–112. doi: 10.1016/j.jsxm.2020.10.001. [DOI] [PubMed] [Google Scholar]
  • 22.Gragasin FS, Michelakis ED, Hogan A, Moudgil R, Hashimoto K, Wu X, Bonnet S, Haromy A, Archer SL. The neurovascular mechanism of clitoral erection: nitric oxide and cGMP- stimulated activation of BKCa channels. FASEB J. 2004;18:1382–1391. doi: 10.1096/fj.04-1978com. [DOI] [PubMed] [Google Scholar]
  • 23.Kim SW, Jeong SJ, Munarriz R, Kim NN, Goldstein I, Traish AM. Role of the nitric oxide-cyclic GMP pathway in regulation of vaginal blood flow. Int J Impot Res. 2003;15:355–361. doi: 10.1038/sj.ijir.3901038. [DOI] [PubMed] [Google Scholar]
  • 24.Doumas M, Tsiodras S, Tsakiris A, Douma S, Chounta A, Papadopoulos A, Kanellakopoulou K, Giamarellou H. Female sexual dysfunction in essential hypertension: a common problem being uncovered. J Hypertens. 2006;24:2387–2392. doi: 10.1097/01.hjh.0000251898.40002.5b. [DOI] [PubMed] [Google Scholar]
  • 25.Gragasin FS, Michelakis ED, Hogan A, Moudgil R, Hashimoto K, Wu X, Bonnet S, Haromy A, Archer SL. The neurovascular mechanism of clitoral erection: nitric oxide and cGMP- stimulated activation of BKCa channels. FASEB J. 2004;18:1382–1391. doi: 10.1096/fj.04-1978com. [DOI] [PubMed] [Google Scholar]
  • 26.Kütmeç C, Yurtsever S. Effects of sexual function of essential hypertensions in women. Eur J Cardiovasc Nurs. 2011;10:56–63. doi: 10.1016/j.ejcnurse.2010.04.004. [DOI] [PubMed] [Google Scholar]
  • 27.Giraldi A, Kristensen E. Sexual dysfunction in women with diabetes mellitus. J Sex Res. 2010;47:199–211. doi: 10.1080/00224491003632834. [DOI] [PubMed] [Google Scholar]
  • 28.Esposito K, Maiorino MI, Bellastella G, Giugliano F, Romano M, Giugliano D. Determinants of female sexual dysfunction in type 2 diabetes. Int J Impot Res. 2010;22:179–184. doi: 10.1038/ijir.2010.6. [DOI] [PubMed] [Google Scholar]
  • 29.Esposito K, Giugliano F, Ciotola M, De Sio M, D’Armiento M, Giugliano D. Obesity and sexual dysfunction, male and female, 2008 nature publishing group. Int J Impot Res. 2008;20(4):358–365. doi: 10.1038/ijir.2008.9. [DOI] [PubMed] [Google Scholar]
  • 30.Faubion SS, Fairbanks F, Kuhle CL, Sood R, Kling JM, Vencill JA, Mara KC, Kapoor E. Association between body mass index and female sexual dysfunction: a cross-sectional study from the data registry on experiences of aging, menopause and sexuality. J Sex Med. 2020;17(10):1971–1980. doi: 10.1016/j.jsxm.2020.07.004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Esposito K, Giugliano D. Obesity, the metabolic syndrome, and sexual dysfunction, 2005 nature publishing group. Int J Impot Res. 2005;17(5):391–398. doi: 10.1038/sj.ijir.3901333. [DOI] [PubMed] [Google Scholar]
  • 32.Limoncin E, Ciocca G, Mollaioli D, Jannini EA. Sexual distress in obesity. In: Lenzi A, Migliaccio S, Donini L, editors. Multidisciplinary approach to obesity. Cham: Springer International Publishing; 2015. pp. 145–153. [Google Scholar]
  • 33.Hayes R, Dennerstein L. The impact of aging on sexual function and sexual dysfunction in women: a review of population-based studies. J Sex Med. 2005;2(3):317–330. doi: 10.1111/j.1743-6109.2005.20356.x. [DOI] [PubMed] [Google Scholar]
  • 34.Esposito K, Ciotola M, Giugliano F, Schisano B, Autorino R, Iuliano S, Vietri MT, Cioffi M, De Sio M, Giugliano D. Mediterranean diet improves sexual function in women with the metabolic syndrome, 2007 nature publishing group. Int J Impot Res. 2007;19(5):486–491. doi: 10.1038/sj.ijir.3901555. [DOI] [PubMed] [Google Scholar]
  • 35.Giugliano F, Maiorino MI, Di Palo C, et al. Adherence to Mediterranean diet and sexual function in women with type 2 diabetes. J Sex Med. 2010;7:1883–1890. doi: 10.1111/j.1743-6109.2010.01714.x. [DOI] [PubMed] [Google Scholar]
  • 36.Peugh J, Belenko S. Alcohol, drugs, and sexual function: a review. J Psychoactive Drugs. 2001;33:223–232. doi: 10.1080/02791072.2001.10400569. [DOI] [PubMed] [Google Scholar]
  • 37.McCall-Hosenfeld JS, Freund KM, Legault C, et al. Sexual satisfaction and cardiovascular disease: the women’s health initiative. Am J Med. 2008;121:295–301. doi: 10.1016/j.amjmed.2007.11.013. [DOI] [PubMed] [Google Scholar]
  • 38.Lutfey KE, Link CL, Rosen RC, et al. Prevalence and correlates of sexual activity and function in women: results from the Boston Area Community Health (BACH) survey. Arch Sex Behav. 2009;38:514–527. doi: 10.1007/s10508-007-9290-0. [DOI] [PubMed] [Google Scholar]
  • 39.Helmrich SP, Ragland DR, Leung RW, Paffenbarger RS., Jr Physical activity and reduced occurrence of non-insulin-dependent diabetes mellitus. N Engl J Med. 1991;325:147–152. doi: 10.1056/NEJM199107183250302. [DOI] [PubMed] [Google Scholar]
  • 40.Skrzypulec V, Dabrowska J, Drosdzol A. The in uence of physical activity level on climacteric symptoms in menopausal women. Climacteric. 2010;13:355–361. doi: 10.3109/13697131003597019. [DOI] [PubMed] [Google Scholar]
  • 41.Li S, Holm K, Gulanick M, Lanuza D, Penckofer S. The relationship between physical activity and perimenopause. Health Care Women Int. 1999;20:163–178. doi: 10.1080/073993399245863. [DOI] [PubMed] [Google Scholar]
  • 42.Llaneza P, Fernández-Ĩnarrea JM, Arnott B, García-Portilla MP, Chedraui P, Pérez-López FR. Sexual function assessment in postmenopausal women with the 14-item changes in sexual functioning questionnaire. J Sex Med. 2011;8:2144–2151. doi: 10.1111/j.1743-6109.2011.02309.x. [DOI] [PubMed] [Google Scholar]
  • 43.Elavsky S, McAuley E, Moti RW, Konopack JF, Marquez DX, Hu L. Longitudinal examination of the exercise and self-esteem model in middleaged women. J Sport Exerc Psychol. 2010;32:862–880. doi: 10.1123/jsep.32.6.862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Cabral PU, Canário AC, Spyrides MH, Uchôa SA, Eleutério Júnior J, Giraldo PC, Gonçalves AK. Physical activity and sexual function in middle-aged women. Rev Assoc Med Bras. 2014;60:47–52. doi: 10.1590/1806-9282.60.01.011. [DOI] [PubMed] [Google Scholar]
  • 45.Kim H-N, Ryu J, Kim K-S, Song S-W. Effects of yoga on sexual function in women with metabolic syndrome: a randomized controlled trial. J Sex Med. 2013;10(11):2741–2751. doi: 10.1111/jsm.12283. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Data Availability Statement

Datasets are available through the corresponding author upon reasonable request.


Articles from Journal of Diabetes and Metabolic Disorders are provided here courtesy of Springer

RESOURCES